Mepranil (Amlodipine, Ramipril)

Mepranil, a combination of a calcium channel blocker and an ACE inhibitor, is indicated for hypertension management.

• Hypertension (essential): reduces systolic and diastolic blood pressure and lowers cardiovascular risk.
• High‑risk hypertensive patients: helps prevent stroke and myocardial infarction.
• Hypertensive patients with renal impairment: provides blood‑pressure control while offering renal protective effects.

• Amlodipine blocks L‑type calcium channels in vascular smooth muscle, causing vasodilation and reduced peripheral resistance. Ramipril inhibits angiotensin‑converting enzyme, decreasing formation of angiotensin II and aldosterone, which leads to vasodilation and reduced sodium‑water retention. The combined actions result in additive blood‑pressure lowering effects.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Peripheral edema: swelling of ankles or feet due to vasodilation.
• Dizziness or light‑headedness: related to blood‑pressure reduction.
• Flushing: transient warmth and redness of the skin.
• Cough: dry, non‑productive cough associated with ACE inhibition.
• Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips, tongue, or airway requiring emergency care.
• Severe hypotension: marked drop in blood pressure causing fainting or shock.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Neutropenia or leukopenia: low white‑blood‑cell counts increasing infection risk.
• Myocardial infarction: rare occurrence of heart attack during treatment.
• Hyperkalemia: elevated potassium levels, especially with potassium‑sparing agents.

Before initiating Mepranil, clinicians should consider several safety measures.

• Blood pressure monitoring: ensure adequate control and avoid excessive hypotension.
• Renal function assessment: adjust dose in patients with impaired kidney function.
• Pregnancy: avoid use unless clearly needed, as safety data are limited.
• Concomitant potassium‑sparing diuretics or supplements: monitor potassium levels to prevent hyperkalemia.
• Hepatic impairment: use with caution and monitor liver enzymes.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Mepranil may interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: combined use can increase risk of renal impairment and hyperkalemia.
• Potassium‑sparing diuretics or potassium supplements: may cause dangerous hyperkalemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can raise amlodipine concentrations and precipitate hypotension.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Other antihypertensives (beta‑blockers, diuretics): increase risk of additive blood‑pressure lowering.
• Lithium: may raise lithium levels, requiring serum monitoring.